National Meeting Highlights from the American Academy of Pain Management 2012
Release Date: November 09, 2012
Expiration Date: November 09, 2013
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This educational initiative offers highlights from 5 key sessions held at the American Academy of Pain Management 2012 meeting. Experts on pain management, addiction medicine, law enforcement, and regulatory issues will offer clinical perspectives on the challenges of managing chronic pain.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in pain management.
Upon completion of this educational activity, participants should be able to:
- Identify and evaluate therapeutic implications of new conference data from the American Academy of Pain Management’s 2012 meeting related to pain management
Understanding REMS Strategies to Maximize Opioid Safety and Efficacy in Chronic Pain – Lynn R. Webster, MD, FACP, FASAM
Preventing Injury and Death from Opioids: Are Dosage Ceilings the Answer? – John J. Coleman, PhD
Rational Polypharmacy – Kathryn L. Hahn, PharmD, DAAPM, CPE
Truth and (Unintended) Consequences: The Effects of Pain Clinic Regulation on Patients and Providers – John F. Peppin, DO, FACP
Rotation of Opioid Adrenergic Combinations – Howard Smith, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 9, 2013. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Jeffrey A. Gudin, MD ‒ Interviewer
Pain Management Center
Englewood Hospital and Medical Center
Englewood, New Jersey
Dr. Jeffrey A. Gudin received his medical degree from Albany Medical College in Albany, New York. Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, New Jersey, he completed a residency in anesthesiology at Yale University School of Medicine. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching. He is currently director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine. Dr. Gudin is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.
An active speaker in the field of pain management, Dr. Gudin has been interviewed on various television news channels, including CBS, and other national news networks. Dr. Gudin has also been quoted in The New York Times and various regional newspapers in New Jersey and Connecticut. His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.
Lynn R. Webster, MD, FACPM, FASAM
Salt Lake City, Utah
Dr. Lynn Webster earned his medical degree from the University of Nebraska and completed his residency in the University of Utah’s Department of Anesthesiology. He is medical director at CRILifetree in Salt Lake City, Utah and is also the co-founder of LifeSource, a non-profit foundation established in 2006 to provide education about pain-related issues as well as fund and conduct research. LifeSource’s first project, “Zero Unintentional Deaths,” was developed to educate physicians, chronic pain sufferers, and all communities about unintentional overdose deaths relating to methadone and other prescription medications.
Dr. Webster is board certified in anesthesiology and pain medicine with additional certification in addiction medicine; he is currently on the Board of Directors and serves as treasurer for the American Academy of Pain Medicine. He is past president of the Utah Academy of Pain Medicine and an active national spokesman for improving access to pain therapies.
Dr. Webster lectures extensively on the subject of preventing opioid abuse and criminal diversion in chronic pain patients. He has authored over 100 scientific abstracts, journal articles and recently published the book, Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners.
John J. Coleman, PhD
President, Drug Watch International
Dr. John Coleman served 32 years as a Special Agent of the US Drug Enforcement Administration (DEA) before retiring in 1998 as one of its top management officials. He began his career in 1965 as an entry-level undercover drug agent on the streets of New York City and went on to eventually hold several of the most important positions in the agency. As assistant administrator for operations, the third highest position in the DEA, Dr. Coleman supervised an annual operating budget of $816 million and managed the activities of over 7,000 employees in 19 domestic divisions and 75 overseas offices. He has extensive executive and policy making experience at the uppermost levels of government service, has served at the highest rank (SES-06) of the Federal Senior Executive Service, and has also served as the assistant administrator for Operations, the highest non-presidentially appointed position in the DEA. Dr. Coleman is currently president of the Board of Directors of Drug Watch International.
Kathryn L. Hahn, PharmD, DAAPM, CPE
Oregon State University College of Pharmacy
Dr. Kathryn Hahn received her pharmacy degree from the University of Southern California, is credentialed as a pain practitioner with the American Academy of Pain Management, and is a certified pain educator. She practices community pharmacy with an emphasis on pain management in Springfield, Oregon. Dr. Hahn is an affiliate faculty member at Oregon State University College of Pharmacy, chairs the Oregon Pain Management Commission, serves on the board of the American Academy of Pain Management as chair of the advocacy committee, and is past president of the Pain Society of Oregon. She has published numerous articles, is a spokesperson for PainSAFE and Good Medicines, Bad Drugs, and is a state pain action leader for the American Pain Foundation. Dr. Hahn speaks both locally and nationally about pain management, its politics, and policy.
John F. Peppin, DO, FACP
Center for Bioethics, Pain Management and Medicine
Des Moines, Iowa
Dr. John Peppin completed his medical degree at the University of Osteopathic Medicine and Health Sciences, Des Moines, Iowa. He continued his postgraduate education with an internal medicine residency at the University of Wisconsin, Marshfield Clinic/St. Joseph’s Hospital. Dr. Peppin is currently director of the Center for Bioethics, Pain Management and Medicine in Des Moines, Iowa, and practices full time pain, palliative and internal medicine in Lexington, Kentucky.
Dr. Peppin is board certified by the American Board of Internal Medicine, American Board of Psychiatry and Neurology, American Board of Pain Medicine, and the American Board of Hospice and Palliative Care Medicine. Additionally, he is a certified Education in Palliative and End-of-Life Care (EPEC) trainer. Dr. Peppin is one of the founding members for the Iowa Pain Management Institute and founding faculty for the University of Integrated Studies in California. He serves on numerous professional committees and is an editor and peer reviewer for numerous journals. Dr. Peppin has published articles in the fields of pain management, palliative care and bioethics, has edited numerous books, and has given numerous lectures at conferences on topics in pain and palliative medicine, bioethics, end-of-life care, and internal medicine.
Howard Smith, MD
Academic Director of Pain Management
Department of Anesthesiology
Albany Medical College,
Albany, New York
Dr. Howard Smith received his medical degree from Rosalind Franklin University of Medicine Science/The Chicago Medical School. He is currently the academic director of pain management, Department of Anesthesiology, Albany Medical College, New York. He is also the assistant director of clinical research at the Pharmaceutical Research Institute, Albany College of Pharmacy.
Dr. Smith is board certified in internal medicine, nuclear medicine, and anesthesiology, and has certification in pain management by both the American Board of Anesthesiology and the American Board of Pain Medicine. He is also certified by the American Board of Hospice and Palliative Medicine, as well as the American Society of Addiction Medicine. Dr. Smith has served as a committee member of the joint pain management examination committee of the American Board of Anesthesiology (ABA), American Board of Physical Medical and Rehabilitation (ABPMR), and American Board of Psychiatry and Neurology (ABPN). He has served as an expert reviewer for a number of publications including Pain, Pain Medicine, Current Pharmaceutical Design, Neuroscience Letters, Pharmacology, Biochemistry and Behavior, Neuromodulation, Journal of Cellular Physiology, and Spine. Dr. Smith also serves as an editor-in-chief of Pain Physician, The Journal of Neuropathic Pain and Symptom Palliation, The Journal of Cancer Pain & Symptom Palliation, and is on the editorial board of the American Journal of Hospice and Palliative Care. In addition, he has lectured at numerous national and international society meetings and authored numerous articles and book chapters, as well as multiple books.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-328-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-328-293
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Pfizer Inc., Purdue Pharma L.P., and Teva Pharmaceuticals.
Dr. Lynn Webster has received honoraria related to formal advisory activities and as a consultant from American Academy of Pain Management, American Board of Pain Medicine, Boston Scientific Corporation, Covidien, Iroko Pharmaceuticals, LLC, Medtronic, Inc., Nektar, Pfizer Inc., and Salix Pharmaceuticals, Inc.
Dr. John Coleman has received honoraria related to formal advisory activities from Covidien, and Meda Pharmaceuticals Inc., as well as consultant fees from Johnson & Johnson Services, Inc.
Dr. Kathryn Hahn and Dr. Howard Smith have disclosed no relevant financial relationships.
Dr. John Peppin has received honoraria related to speakers’ bureau activities from AIKO Biotechnology, Inc.; Ameritox, Ltd.; Eli Lilly and Company; Pfizer Inc.; Salix Pharmaceuticals, Inc.; Shionogi Inc.; Theravance, Inc.; and Trevena, Inc. He has received grant support related to research activities from AstraZeneca; Teva Pharmaceuticals; Pfizer; NeurogesX; and Shionogi.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Bronwyn Boyes, PharmD, director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Gudin, Coleman, Peppin, and Smith have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Gudin, Webster, Coleman, Peppin, and Smith have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Webster and Dr. Hahn have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Hahn has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Endo Pharmaceuticals and Salix Pharmaceuticals, Inc.
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.